Savill Corrine's Form 4 filing
Cullinan Therapeutics, Inc. (CGEM) · filed Jan 30, 2024
- Accession no.
- 0000950170-24-009047
- Filed
- Jan 30, 2024
- Trade date
- Jan 29, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $563.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Savill CorrineCIK 0001837524 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | MOption exerciseAcquired | +40,000 | $4.30 | +$172,000 | 205,990 | Direct | |
| Jan 29, 2024 | Common Stock | SSaleDisposed | −40,000 | $14.09 | −$563,600 | 165,990 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | MOption exerciseDisposed | −13,997 | $0.00 | $0 | 0 | Direct | |
| Jan 29, 2024 | Common Stock | MOption exerciseDisposed | −26,003 | $0.00 | $0 | 110,331 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.